Thursday, October 3, 2019

Regenerative Medicine Market is valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% During Forecasted Year 2017-2023


KD Market research has presented a detailed report on  “Regenerative Medicine Market which includes the major application, advantages, and key market trends that are fostering the growth of the market during the forecasted span of 7 years. The research takes a step forward and analyzes the key competitors and global regions that are holding the market share of Regenerative Medicine Market in terms of revenue.

The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines repair, replace, and regenerate tissues and organs affected due to injury, disease, or natural ageing process. These medicines help restore the functionality of cells & tissues and are applicable in numerous degenerative disorders such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. Researchers focus on developing technologies based on biologics, genes, somatic as well as stem cells. Stem cells are capable of proliferation and differentiation and hence, are critical in this field.


The major factors that boost the market growth include technological advancements in tissue and organ regeneration, increase in prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, rise in degenerative diseases and shortage of organs for transplantation are expected to fuel the growth of the market. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened numerous growth avenues for the regenerative medicines market. However, stringent regulatory barriers and high cost of the treatment are likely to hinder the market growth.

The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. 

Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

This report offers a detailed quantitative analysis of the market trends from 2016 to 2023 to identify the prevailing opportunities.

The market estimations provided in this report are based on a comprehensive analysis of the key developments in the industry.

An in-depth analysis based on geography facilitates the study of the regional market to assist in strategic business planning.

The development strategies adopted by the key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Product Type
Cell Therapy
Gene Therapy
Tissue Engineering
Small Molecule & Biologic

By Material
Synthetic Material
Biodegradable Synthetic Polymer
Scaffold
Artificial Vascular Graft Material
Hydrogel Material
Biologically Derived Material
Collagen
Xenogeneic Material
Genetically Engineered Material
Deoxyribonucleic Acid Transfection Vectors
Three-Dimensional Polymer Technology
Transgenic
Fibroblast
Neural Stem Cell
Gene-Activated Matrices
Pharmaceuticals
Small Molecule
Biologic

By Application
Cardiovascular
Oncology
Dermatology
Musculoskeletal
Wound Healing
Ophthalmology
Neurology
Others

By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Russia
Netherlands
Sweden
Rest of Europe

Asia-Pacific
Japan
China
Australia
India
Singapore

Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA

KEY PLAYERS PROFILED
Stryker Corporation
Zimmer Biomet Holdings, Inc.
Medtronic Plc.
Athersys, Inc.
U.S. Stem Cell, Inc. (Bioheart, Inc.)
Organogenesis, Inc. (Advanced Biohealing)
Integra Lifesciences Holdings Corporation
Acelity Holdings, Inc.
Isto Biologics (Isto Biologics Medical Systems, Inc.)
CryoLife, Inc.

The other players of the Regenerative Medicine market include (companies not profiled in the report):

Shimadzu Recursion Pharmaceuticals, Inc.
Baxter International, Inc.
DePuy Synthes
Siemens Healthineers
General Electric (GE) Company
Koninklijke Philips N.V.
Cloudmedx, Inc.
Bay Labs, Inc.


Table of content

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments

1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market Definition And Scope

3.2. Key Findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Porters Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers

3.4.1.1. High adoption of stem cell technology
3.4.1.2. Emerging application of nanotechnology
3.4.1.3. Increasing prevalence of chronic diseases and trauma emergencies
3.4.1.4. Advancements in medical equipment technologies

3.4.2. Restraints
3.4.2.1. Ethical hurdles
3.4.2.2. Costly treatment associated with regenerative medicine

3.4.3. Opportunities
3.4.3.1. Lucrative opportunities of novel stem cell technologies
3.4.3.2. Increasing potential in emerging economies
3.4.3.3. Growing need of regenerative medicine in organ transplantation

CHAPTER 4: REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE

4.1. Overview
4.1.1. Market size and forecast

4.2. Cell Therapy
4.2.1. Key market trends
4.2.2. Key growth factors and growth opportunities
4.2.3. Market size and forecast

4.3. Gene Therapy
4.3.1. Key market trends
4.3.2. Key growth factors and growth opportunities
4.3.3. Market size and forecast

4.4. Tissue Engineering
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. Small Molecules And Biologics
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

CHAPTER 5: REGENERATIVE MEDICINE MARKET, BY MATERIAL

5.1. Overview
5.1.1. Market size and forecast

5.2. Synthetic Materials
5.2.1. Market size and forecast, by region
5.2.2. Market size and forecast, by type

5.2.3. Biodegradable synthetic polymers
5.2.3.1. Market size and forecast

5.2.4. Scaffold
5.2.4.1. Market size and forecast

5.2.5. Artificial vascular graft materials
5.2.5.1. Market size and forecast

5.2.6. Hydrogel material
5.2.6.1. Market size and forecast

5.3. Biologically Derived Materials
5.3.1. Market size and forecast, by region
5.3.2. Market size and forecast, by type

5.3.3. Collagen
5.3.3.1. Market size and forecast

5.3.4. Xenogeneic material
5.3.4.1. Market size and forecast

5.4. Genetically Engineered Materials
5.4.1. Market size and forecast, by region
5.4.2. Market size and forecast, by type

5.4.3. Deoxyribonucleic acid transfection vectors
5.4.3.1. Market size and forecast

5.4.4. Genetically manipulated cells
5.4.4.1. Market size and forecast

5.4.5. Three-dimensional polymer technology
5.4.5.1. Market size and forecast

5.4.6. Transgenics
5.4.6.1. Market size and forecast

5.4.7. Fibroblasts
5.4.7.1. Market size and forecast

5.4.8. Neural stem cells
5.4.8.1. Market size and forecast

5.4.9. Gene-activated matrices
5.4.9.1. Market size and forecast

5.5. Pharmaceuticals

5.5.1. Market size and forecast, by region
5.5.2. Market size and forecast, by type

5.5.3. Small molecules

5.5.3.1. Market size and forecast
5.5.4. Biologics

5.5.4.1. Market size and forecast

CHAPTER 6: REGENERATIVE MEDICINE MARKET, BY APPLICATION

6.1. Overview
6.1.1. Market size and forecast

6.2. Cardiovascular
6.2.1. Market size and forecast

6.3. Oncology
6.3.1. Market size and forecast

6.4. Dermatology
6.4.1. Market size and forecast

6.5. Musculoskeletal
6.5.1. Market size and forecast

6.6. Wound Healing
6.6.1. Market size and forecast

6.7. Ophthalmology
6.7.1. Market size and forecast

6.8. Neurology
6.8.1. Market size and forecast

6.9. Others
6.9.1. Market size and forecast

CHAPTER 7: REGENERATIVE MEDICINE MARKET, BY REGION

7.1. Overview
7.1.1. Market size and forecast

7.2. North America
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast, by product type
7.2.4. Market size and forecast, by material
7.2.5. Market size and forecast, by application

7.2.6. Market size and forecast, by country
7.2.6.1. U.S. market size and forecast
7.2.6.2. Canada market size and forecast
7.2.6.3. Mexico market size and forecast

7.3. Europe
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast, by product type
7.3.4. Market size and forecast, by material
7.3.5. Market size and forecast, by application

7.3.6. Market size and forecast, by country
7.3.6.1. Germany market size and forecast
7.3.6.2. France market size and forecast
7.3.6.3. UK market size and forecast
7.3.6.4. Italy market size and forecast
7.3.6.5. Spain market size and forecast
7.3.6.6. Russia market size and forecast
7.3.6.7. Rest of Europe market size and forecast

7.4. Asia-Pacific
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast, by product type
7.4.4. Market size and forecast, by material
7.4.5. Market size and forecast, by application

7.4.6. Market size and forecast, by country
7.4.6.1. Japan market size and forecast
7.4.6.2. China market size and forecast
7.4.6.3. Australia market size and forecast
7.4.6.4. India market size and forecast
7.4.6.5. South Korea market size and forecast
7.4.6.6. Taiwan market size and forecast
7.4.6.7. Rest of Asia-Pacific market size and forecast

7.5. Lamea
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast, by product type
7.5.4. Market size and forecast, by material
7.5.5. Market size and forecast, by application

7.5.6. Market size and forecast, by country
7.5.6.1. Brazil market size and forecast
7.5.6.2. Turkey market size and forecast
7.5.6.3. Venezuela market size and forecast
7.5.6.4. Saudi Arabia market size and forecast
7.5.6.5. South Africa market size and forecast
7.5.6.6. Rest of LAMEA market size and forecast

CHAPTER 8: COMPANY PROFILES

8.1. Acelity Holdings, Inc. (Lifecell Corporation)
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Key strategic moves and developments

8.2. Athersys, Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. Cryolife, Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance

8.4. Integra Lifesciences Corporation
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments

8.5. Isto Biologics (Isto Biologics Medical Systems, Inc.)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Key strategic moves and developments

8.6. Medtronic Plc
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance

8.7. Organogenesis Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Key strategic moves and developments

8.8. Stryker Corporation
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments

8.9. U.S. Stem Cell, Inc. (Bioheart, Inc.)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. Zimmer Biomet Holdings, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments


About Us:

KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.

Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.

Contact us - KD Market Research
150 State Street, Albany,
New York, USA 12207


No comments:

Post a Comment